Significant evidence has accumulated that PITX2 methylation predicts outcome in lymph node-positive, ER positive, HER2 negative breast cancer patients to adjuvant anthracycline-based chemotherapy and, thus, will support the clinicians to the most effective therapy option13,14. Here, PITX2 is linked to breast cancer.